INOVIO Announces Pricing of $20.0 Million Public Offering

Rhea-AI Summary

INOVIO (Nasdaq: INO) priced an underwritten public offering of 21,052,632 common shares and accompanying warrants to purchase up to 42,105,264 shares (or pre-funded warrants) at a combined public price of $0.95 per share and two warrants, with a warrant exercise price of $1.10 per share.

According to INOVIO, the underwriter has a 30-day option to buy up to 3,157,894 additional shares and/or warrants to purchase 6,315,788 shares. All securities are being sold by the company, which expects gross proceeds of approximately $20.0 million before fees, with closing anticipated around July 31, 2026. Piper Sandler is sole manager.

Positive

• $20.0 million expected gross proceeds before fees and expenses
• All offered securities sold by INOVIO, providing direct capital inflow
• Underwriter 30-day option for up to 3.16 million extra shares and warrants
• Warrants for up to 42.1 million shares could raise additional cash if exercised

Negative

• Base offering of 21.1 million new shares implies substantial dilution
• Warrants for up to 42.1 million shares add further potential dilution
• Combined offering price of $0.95 per share and warrants reflects low equity pricing

News Explained

If it closes, new shares dilute existing ownership; warrants add contingent dilution, while expected gross proceeds equal 83.4 days of first-quarter operating cash use.

The priced offering remains pending closing; if completed, the company-sold common shares would increase total share count and reduce existing holders’ percentage ownership, while the warrants create a further path to share issuance if exercised.

A pre-funded warrant offered in lieu of common shares converts into shares on exercise and is structured with a near-full purchase price and nominal exercise price; it is therefore a conversion route rather than an immediate additional share issuance.

As a historical sizing comparison, the expected gross proceeds equal 83.4 days of the last reported operating cash use. First-quarter cash and equivalents were $26,271,650, alongside $11,409,607 of short-term investments.

The July 2 shelf registration authorizes future sales but is not itself another share sale; the priced transaction is the specific takedown whose final terms belong in its prospectus supplement.

Sources and calculations

• INOVIO Announces Pricing of $20.0 Million Public Offering (2026-07-29)
• Dilution (2026-07-17)
• Pre-funded warrant (2026-07-17)
• Form S-3 purpose (2026-07-17)
• Prospectus supplement purpose (2026-07-17)
• INOVIO first-quarter 2026 fundamentals (2026Q1)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $20,000,000 / ($21,591,316 / 90) = 83.4 days

Argus Jul 30 session 72 alerts

-36.92% close to close 18.7x rel. volume Open Argus

Details

Market reaction after $20M public offering: INO -36.92% in the Jul 30 session

-47.5% Trough in 24 hr 48 min

$83.64M Market Cap

In the Jul 30 session, INO declined 36.92%, reflecting a significant negative market reaction. Argus tracked a trough of -47.5% from its starting point during tracking. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 18.7x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -36.9% in the session following this news. A prior INOVIO offering was followed by...

Analysis

The stock dropped -36.9% in the session following this news. A prior INOVIO offering was followed by a -37.85% 24-hour reaction. The active S-3 shelf, filed July 2 and effective July 10, supported the current financing framework. High short positioning remained a volatility risk.

Key Figures

Gross proceeds: $20.0 million Common shares: 21,052,632 shares Accompanying warrants: 42,105,264 warrants +5 more

Gross proceeds

$20.0 million

Offering, before discounts and expenses

Common shares

21,052,632 shares

Public offering

Accompanying warrants

42,105,264 warrants

Warrants to purchase common stock

Warrant exercise price

$1.10 per share

Accompanying warrants

Combined offering price

$0.95 per share

Common stock and accompanying warrant to purchase two shares

Underwriter option period

30 days

Option to purchase additional securities

Additional option securities

3,157,894 shares and 6,315,788 warrants

Underwriter option

Expected closing

July 31, 2026

Subject to customary closing conditions

Previous Offering Reports

5 past events · Latest: Apr 02

Same Type 5 events

1. Apr 02

   Offering pricing

   24h Move

   -35.1%

   Priced common shares and warrants; the stock recorded a -35.06% 24-hour reaction.

2. Apr 01

   Offering proposal

   24h Move

   -35.1%

   Announced a proposed offering; the stock recorded a -35.06% 24-hour reaction.

3. Nov 11

   Offering pricing

   24h Move

   -7.0%

   Priced common shares; the stock recorded a -6.98% 24-hour reaction.

4. Nov 10

   Offering proposal

   24h Move

   -7.0%

   Announced a proposed offering; the stock recorded a -6.98% 24-hour reaction.

5. Jul 03

   Offering pricing

   24h Move

   -37.9%

   Priced common shares and warrants; the stock recorded a -37.85% 24-hour reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, prospectus supplement

4 terms

underwritten public offering financial

"announced the pricing of an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"or pre-funded warrants in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement relating to the shares"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of the Company's common stock and/or warrants to purchase up to 6,315,788 additional shares of its common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, and excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying warrants, are expected to be approximately $20.0 million.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-pricing-of-20-0-million-public-offering-302838434.html

SOURCE Inovio Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of INOVIO (NASDAQ: INO) July 2026 public offering?

INOVIO priced 21,052,632 shares with warrants for up to 42,105,264 shares at $0.95 per share-and-warrant unit. According to INOVIO, warrant exercise price is $1.10 per share, and all securities in the deal are being sold by the company.

How much money will INOVIO (INO) raise from its $20 million stock and warrant offering?

INOVIO expects gross proceeds of approximately $20.0 million before underwriting discounts, commissions, and expenses. According to INOVIO, this estimate excludes any exercise of the underwriter’s option and assumes no exercise of the accompanying warrants issued in the offering.

How dilutive is the July 2026 INOVIO public offering to existing INO shareholders?

The offering adds 21,052,632 new shares plus warrants for up to 42,105,264 additional shares. According to INOVIO, the underwriter may also buy more shares and warrants, increasing potential dilution if all securities and warrants are ultimately issued and exercised.

When is the INOVIO (INO) July 2026 public offering expected to close?

The offering is expected to close on or about July 31, 2026, subject to customary closing conditions. According to INOVIO, Piper Sandler is acting as sole manager for the transaction under an effective shelf registration statement.

What is the exercise price and structure of the warrants in INOVIO’s July 2026 offering?

Each share is sold with accompanying warrants to purchase two additional shares, exercisable at $1.10 per share. According to INOVIO, total warrants cover up to 42,105,264 shares, with pre-funded warrants possibly issued in lieu of standard warrants.

Does INOVIO’s July 2026 offering include an underwriter overallotment option for INO stock?

Yes. The underwriter has a 30-day option to purchase up to 3,157,894 additional shares and/or warrants for 6,315,788 shares. According to INOVIO, these would be sold at the public offering price, less underwriting discounts and commissions.